This is a first in human clinical trial utilizing CD34+ selected allografts with gene-edited CD33neg hematopoietic stem cells from HLA matched related or unrelated donors for patients with AML – Guenther Koehne

It’s been my privilege to present first results of the VOR study VBP101, here at the European Hematology Association (EHA) 2023. This is a first in human clinical trial utilizing CD34+ selected allografts with gene-edited CD33neg hematopoietic stem cells from HLA matched related or unrelated donors for patients with AML. We reported a timely engraftment of all cell lineages of five patients transplanted with CD34+CD33- hematopoietic stem cells when compared to non-gene edited CD34+ selected allografts, thus providing a potential new platform of targeting CD33 expressing leukemia cells post allogeneic stem cell transplants.

Source: Guenther Koehne/Linkedin